TARC After alloSCT in Hodgkin's Lymphoma

Completed

• Conditions: Hodgkin's Lymphoma Patients Who Underwent an Allogeneic Stem Cell Transplantation
• Interventions: Other: no treatment

• Registration Number: NCT02069639
• Lead Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Brief Summary

Relapsed and refractory Hodgkin's lymphoma (HL) patients may experience long-term survival after allogeneic transplant (alloSCT), but disease recurrence represents the main cause of treatment failure. PET (positron-emission tomography) -positive patients after alloSCT have a dismal outcome. Serum TARC (thymus and activation-regulated chemokine) is produced by Reed-Sternberg cells and may be a marker of disease. Our study was aimed at assessing whether TARC levels after alloSCT were correlated to disease status and whether TARC monitoring could increase the ability to predict relapse.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-11
• Primary Completion: 2014-01
• Study Completion: 2014-01
• Status Verified: 2014-02
• Study First Submitted: 2014-02-14
• Study First Submitted QC: 2014-02-20
• Last Update Submitted: 2014-02-20
• Study First Posted: 2014-02-24
• Last Update Posted: 2014-02-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

• Hodgkin's lymphoma patients who underwent an alloSCT at Fondazione IRCCS Istituto Nazionale dei Tumori and who were monitored by PET and TARC before and after alloSCT from 2009

Exclusion Criteria

• Hodgkin's lymphoma patients who underwent an alloSCT who were not monitored by PET or/and TARC

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
no treatment	no treatment	-

Primary Outcome Measures

Name	Time	Method
Correlation between disease status and serum TARC level	One year after transplant	Serum TARC level was measured before alloSCT in Hodgkin's lymphoma patients and after alloSCT. The median time interval after alloSCT was 47 days. PFS was estimated at one year based on TARC value.

Secondary Outcome Measures

Name	Time	Method
The correlation between TARC levels and PET results after alloSCT	Before alloSCT, monthly during the first 6 months after alloSCT and every 2 months until 2 years of follow-up, then at the time of clinical check-up (usually every 6 months)	We selected TARC values done on the days of PET to assess a cut-off value of TARC that was correlated to a positive or negative PET

Trial Locations

Locations (1)

Fondazione IRCCS Istituto Nazionale dei Tumori; 🇮🇹 Milan, Italy